These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35580298)

  • 1. Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533.
    Madanat-Harjuoja LM; Renfro LA; Klega K; Tornwall B; Thorner AR; Nag A; Dix D; Dome JS; Diller LR; Fernandez CV; Mullen EA; Crompton BD
    J Clin Oncol; 2022 Sep; 40(26):3047-3056. PubMed ID: 35580298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group.
    Gratias EJ; Dome JS; Jennings LJ; Chi YY; Tian J; Anderson J; Grundy P; Mullen EA; Geller JI; Fernandez CV; Perlman EJ
    J Clin Oncol; 2016 Sep; 34(26):3189-94. PubMed ID: 27400937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.
    Dix DB; Fernandez CV; Chi YY; Mullen EA; Geller JI; Gratias EJ; Khanna G; Kalapurakal JA; Perlman EJ; Seibel NL; Ehrlich PF; Malogolowkin M; Anderson J; Gastier-Foster J; Shamberger RC; Kim Y; Grundy PE; Dome JS;
    J Clin Oncol; 2019 Oct; 37(30):2769-2777. PubMed ID: 31449468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children's Oncology Group.
    Gratias EJ; Jennings LJ; Anderson JR; Dome JS; Grundy P; Perlman EJ
    Cancer; 2013 Nov; 119(21):3887-94. PubMed ID: 23983061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
    Chagtai T; Zill C; Dainese L; Wegert J; Savola S; Popov S; Mifsud W; Vujanić G; Sebire N; Le Bouc Y; Ambros PF; Kager L; O'Sullivan MJ; Blaise A; Bergeron C; Mengelbier LH; Gisselsson D; Kool M; Tytgat GA; van den Heuvel-Eibrink MM; Graf N; van Tinteren H; Coulomb A; Gessler M; Williams RD; Pritchard-Jones K
    J Clin Oncol; 2016 Sep; 34(26):3195-203. PubMed ID: 27432915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study.
    Dix DB; Seibel NL; Chi YY; Khanna G; Gratias E; Anderson JR; Mullen EA; Geller JI; Kalapurakal JA; Paulino AC; Perlman EJ; Ehrlich PF; Malogolowkin M; Gastier-Foster JM; Wagner E; Grundy PE; Fernandez CV; Dome JS
    J Clin Oncol; 2018 Jun; 36(16):1564-1570. PubMed ID: 29659330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.
    Fernandez CV; Mullen EA; Chi YY; Ehrlich PF; Perlman EJ; Kalapurakal JA; Khanna G; Paulino AC; Hamilton TE; Gow KW; Tochner Z; Hoffer FA; Withycombe JS; Shamberger RC; Kim Y; Geller JI; Anderson JR; Grundy PE; Dome JS
    J Clin Oncol; 2018 Jan; 36(3):254-261. PubMed ID: 29211618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.
    Bown N; Cotterill SJ; Roberts P; Griffiths M; Larkins S; Hibbert S; Middleton H; Kelsey A; Tritton D; Mitchell C
    Med Pediatr Oncol; 2002 Jan; 38(1):11-21. PubMed ID: 11835232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
    Abbou S; Klega K; Tsuji J; Tanhaemami M; Hall D; Barkauskas DA; Krailo MD; Cibulskis C; Nag A; Thorner AR; Pollock S; Imamovic-Tuco A; Shern JF; DuBois SG; Venkatramani R; Hawkins DS; Crompton BD
    J Clin Oncol; 2023 May; 41(13):2382-2393. PubMed ID: 36724417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of lymph node involvement and loss of heterozygosity of 1p or 16q in stage III favorable histology Wilms tumor: A report from Children's Oncology Group Studies AREN03B2 and AREN0532.
    Evageliou N; Renfro LA; Geller J; Perlman E; Kalapurakal J; Paulino A; Dix D; Eklund MJ; Murphy AJ; Romao RLP; Ehrlich PF; Varela CR; Vallance K; Fernandez CV; Dome JS; Mullen EA
    Cancer; 2024 Mar; 130(5):792-802. PubMed ID: 37902955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis.
    Jiménez I; Chicard M; Colmet-Daage L; Clément N; Danzon A; Lapouble E; Pierron G; Bohec M; Baulande S; Berrebi D; Fréneaux P; Coulomb A; Galmiche-Rolland L; Sarnacki S; Audry G; Philippe-Chomette P; Brisse HJ; Doz F; Michon J; Delattre O; Schleiermacher G
    Int J Cancer; 2019 Jan; 144(1):68-79. PubMed ID: 29923174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.
    Fernandez CV; Perlman EJ; Mullen EA; Chi YY; Hamilton TE; Gow KW; Ferrer FA; Barnhart DC; Ehrlich PF; Khanna G; Kalapurakal JA; Bocking T; Huff V; Tian J; Geller JI; Grundy PE; Anderson JR; Dome JS; Shamberger RC
    Ann Surg; 2017 Apr; 265(4):835-840. PubMed ID: 27811504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of children with favorable histology Wilms tumor with extrapulmonary metastases: A report from the COG studies AREN0533 and AREN03B2 and NWTSG study NWTS-5.
    Benedetti DJ; Varela CR; Renfro LA; Tornwall B; Dix DB; Ehrlich PF; Glick RD; Kalapurakal J; Perlman E; Gratias E; Seibel NL; Geller JI; Khanna G; Malogolowkin M; Grundy P; Fernandez CV; Dome JS; Mullen EA
    Cancer; 2024 Mar; 130(6):947-961. PubMed ID: 37933882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation of 1p/16q loss of heterozygosity and 1p gain with clinicopathological characteristics and prognosis in Wilms tumor].
    Jia C; Yao XF; Zhang M; Guan XX; Wang JW; Song HC; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):257-263. PubMed ID: 38433053
    [No Abstract]   [Full Text] [Related]  

  • 15. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group.
    Grundy PE; Breslow NE; Li S; Perlman E; Beckwith JB; Ritchey ML; Shamberger RC; Haase GM; D'Angio GJ; Donaldson M; Coppes MJ; Malogolowkin M; Shearer P; Thomas PR; Macklis R; Tomlinson G; Huff V; Green DM;
    J Clin Oncol; 2005 Oct; 23(29):7312-21. PubMed ID: 16129848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Profiling Loss of Heterozygosity Patterns in a Cohort of Favorable Histology Nephroblastoma Egyptian Patients: What is Consistent With the Rest of the World.
    Fawzy M; Bahanassy A; Samir A; Hafez H
    Pediatr Hematol Oncol; 2015; 32(8):548-56. PubMed ID: 26390800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
    Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
    Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG).
    Park JE; Noh OK; Lee Y; Choi HS; Han JW; Hahn SM; Lyu CJ; Lee JW; Yoo KH; Koo HH; Jeong SY; Sung KW
    Cancer Res Treat; 2020 Apr; 52(2):438-445. PubMed ID: 31505910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors.
    Smith CG; Moser T; Mouliere F; Field-Rayner J; Eldridge M; Riediger AL; Chandrananda D; Heider K; Wan JCM; Warren AY; Morris J; Hudecova I; Cooper WN; Mitchell TJ; Gale D; Ruiz-Valdepenas A; Klatte T; Ursprung S; Sala E; Riddick ACP; Aho TF; Armitage JN; Perakis S; Pichler M; Seles M; Wcislo G; Welsh SJ; Matakidou A; Eisen T; Massie CE; Rosenfeld N; Heitzer E; Stewart GD
    Genome Med; 2020 Feb; 12(1):23. PubMed ID: 32111235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer.
    Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.